Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Zachary Brennan

Senior Editor

Donald Trump’s embrace of Robert F. Kennedy Jr. is forcing biotech and pharma leaders to grapple with having US life sciences policy influenced by a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Nvidia-backed Achira debuts, blending AI and physics to model molecules

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins